Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;6(2):e1700.
doi: 10.1002/cnr2.1700. Epub 2022 Aug 10.

The NBN founder mutation-Evidence for a country specific difference in age at cancer manifestation

Krystyna H Chrzanowska  1 , Eva Seemanova  2 , Raymonda Varon  3 , Martin Digweed  3 , Dorota Piekutowska-Abramczuk  1 , Karl Sperling  3 , Pavel Seeman  4
Affiliations

The NBN founder mutation-Evidence for a country specific difference in age at cancer manifestation

Krystyna H Chrzanowska et al. Cancer Rep (Hoboken). 2023 Feb.

Abstract

Background: Nijmegen breakage syndrome (NBS) is an autosomal-recessive chromosome instability disorder characterized by, among others, hypersensitivity to X-irradiation and an exceptionally high risk for lymphoid malignancy. The vast majority of NBS patients is homozygous for a common Slavic founder mutation, c.657del5, of the NBN gene, which is involved in the repair of DNA double-strand breaks (DSBs). The founder mutation also predisposes heterozygous carriers to cancer, apparently however, with a higher risk in the Czech Republic/Slovakia (CS) than in Poland.

Aim: To examine whether the age of cancer manifestation and cancer death of NBN homozygotes is different between probands from CS and Poland.

Methods: The study is restricted to probands born until 1989, before replacement of the communist regime by a democratic system in CS and Poland, and a substantial transition of the health care systems. Moreover, all patients were recruited without knowledge of their genetic status since the NBN gene was not identified until 1998.

Results: Here, we show that cancer manifestation of NBN homozygotes is at a significantly earlier age in probands from CS than from Poland. This is explained by the difference in natural and medical radiation exposure, though within the permissible dosage.

Conclusion: It is reasonable to assume that this finding also sheds light on the higher cancer risk of NBN heterozygotes in CS than in Poland. This has implications for genetic counseling and individualized medicine also of probands with other DNA repair defects.

Keywords: NBS; age of cancer manifestation; cancer risk of heterozygotes; environmental and medical exposure to ionizing radiation.

PubMed Disclaimer

Conflict of interest statement

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Figures

FIGURE 1
FIGURE 1
Indoor radon concentrations in 32 European countries, estimated in 10 × 10 km cells. Given is the percentage of cells with an arithmetic mean (AM) above 100 and 300 Bq/m3. Inset: Map of estimated indoor radon concentrations across Europe, especially Czechia (CZ) and Poland (PL). The doses were estimated in 10 × 10 km cells and depicted as arithmetic means
See this image and copyright information in PMC

References

    1. Chrzanowska KH, Gregorek H, Dembowska‐Baginska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis. 2012;7:13. - PMC - PubMed
    1. Varon R, Vissinga C, Platzer M, et al. Nibrin, a novel DNA double‐strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell. 1998;93:467‐476. - PubMed
    1. Digweed M, Sperling K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double‐strand breaks. DNA Repair (Amst). 2004;3:1207‐1217. - PubMed
    1. Lamarche BJ, Orazio NI, Weitzman MD. The MRN complex in double‐strand break repair and telomere maintenance. FEBS Lett. 2010;584:3682‐3695. - PMC - PubMed
    1. Komatsu K. NBS1 and multiple regulations of DNA damage response. J Radiat Res. 2016;57(Suppl 1):i11‐i17. - PMC - PubMed

Publication types